Morgan Stanley’s Ayala Pharmaceuticals, Inc. Common Stock AYLA Stock Holding History

Morgan Stanley’s Portfolio AYLA Stock Details AYLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,931	Closed	-$5.57K	–	7985
2022 Q4	$5.57K	Sell	13,931 -2,400	-15%	-$1.56K	﹤0.01%	7119
2022 Q3	$16K	Buy	16,331 +15,971	+4,436%	+$21.5K	﹤0.01%	6906
2022 Q2	$0	Sell	360 -1,717	-83%	-$3.92K	﹤0.01%	8156
2022 Q1	$8K	Buy	2,077 +380	+22%	+$1.98K	﹤0.01%	7483
2021 Q4	$14K	Buy	1,697 +1,337	+371%	+$13.3K	﹤0.01%	7360
2021 Q3	$4K	Hold	360	–	–	﹤0.01%	7569
2021 Q2	$4K	Sell	360 -3,813	-91%	-$39.2K	﹤0.01%	7463
2021 Q1	$46K	Buy	+4,173	New	+$59.6K	﹤0.01%	6388

Morgan Stanley's AYLA Position: Q1 2023 in Review

Morgan Stanley sold out of Ayala Pharmaceuticals, Inc. Common Stock (AYLA) in Q1 2023, closing a stake of 13,931 shares — an estimated $5.57K sold.

Morgan Stanley first reported a position in AYLA in Q1 2021 and held it in 8 quarters. The position peaked at $46K in Q1 2021. 0 funds tracked by Wall St. Rank hold AYLA as of Q1 2023.

Morgan Stanley reported no remaining Ayala Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Morgan Stanley sold 13,931 Ayala Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $5.57K.
Morgan Stanley first reported a position in Ayala Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Morgan Stanley's Ayala Pharmaceuticals, Inc. Common Stock position peaked at $46K in Q1 2021.
0 funds tracked by Wall St. Rank held Ayala Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.